In this interview, Sebastiaan J. Trietsch, Chief Technology Officer at MIMETAS, discusses how microphysiological systems are ...

As with its predecessor, the new drug candidate, Jun13296, targets a different viral protein than Paxlovid does and works ...

The development of long-acting drug depots represents a significant advancement in pharmaceutical technology, offering ...

Drug A killed all the rats ... Indeed, given that problems exist because scientists must extrapolate from animal models to humans, one might think there are good scientific reasons for preferring ...

In attempt to keep R&D costs low, the vivarium business model has emerged as a crucial solution for drug developers.

Alzheimer's disease, the most common cause of dementia, is currently incurable. The current drugs available have very limited efficacy and only in mild stages of the disease.